Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.

被引：2
|
作者：
Vilbert, Maysa
Priantti, Jonathan N.
Madeira, Thiago
Moraes, Francisco Cezar A.
Tojjari, Alireza
Sahin, Ibrahim Halil
Cavalcante, Ludimila
Saeed, Anwaar
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Fed Univ Amazonas UFAM, Manaus, AM, Brazil
[3] Fed Univ Minas Gerais UFMG, Belo Horizonte, MG, Brazil
[4] Fed Univ Para UFPA, Belem, PA, Brazil
[5] Novant Hlth Canc Inst, Charlotte, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-566-9718-9794; 261-492-3532-2370-7650-2700; 283-424-6846-271-2644; 283-2494; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 7; 4; 3; 2; 1614; 1597; 8; 1; 38092-27449; 38092-20072; 6;
D O I：
10.1200/JCO.2024.42.3_suppl.366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：366 / 366
页数：1
相关论文
共 50 条
  • [1] Anti-PD1 antibodies plus chemotherapy for first-line treatment of advanced oesophageal squamous cell carcinoma
    Qian, J.
    Lin, W.
    Wang, H.
    Du, X.
    Wu, M.
    Huang, Y.
    Xu, N.
    Teng, L.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1749 - 1749
  • [2] Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma
    Chen, Qin
    Wang, Jing
    Wang, Xinyue
    Yin, Yan
    Wang, Xuan
    Song, Zhenchun
    Xing, Bin
    Li, Yajing
    Zhang, Jingjing
    Qin, Jianwen
    Jiang, Richeng
    CLINICAL LUNG CANCER, 2024, 25 (01) : 29 - 38
  • [3] Comments on "Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma"
    Huang, Jie
    CLINICAL LUNG CANCER, 2024, 25 (08) : e446 - e447
  • [4] Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Jiang, Jun
    Zhang, Xin
    Liu, Yun
    Mu, Lan
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma
    Zheng, Hanrui
    Li, Jiafeng
    Wen, Feng
    Su, Na
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Dun-Chang Mo
    Jian-Feng Huang
    Peng-Hui Luo
    Long Chen
    Biao Zou
    Han-Lei Wang
    European Archives of Oto-Rhino-Laryngology, 2023, 280 : 1 - 9
  • [8] PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
    Mo, Dun-Chang
    Huang, Jian-Feng
    Luo, Peng-Hui
    Chen, Long
    Zou, Biao
    Wang, Han-Lei
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2023, 280 (01) : 1 - 9
  • [9] SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study
    Mu, Lan
    Song, Yan
    Zhao, Kuaile
    Liu, Ying
    Fan, Qingxia
    Wang, Xi
    Li, Qun
    Wang, Xiaopeng
    Huang, Jing
    THORACIC CANCER, 2021, 12 (09) : 1373 - 1381
  • [10] Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1%.
    Landre, Thierry
    Guetz, Gaetan Des
    Chouahnia, Kader
    Taleb, Cherifa
    Vergnenegre, Alain
    Chouaid, Christos
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345